Medicalgorithmics doubled the number of ECG examinations in Q1 2025.Service revenues in the U.S. increased by 52% quarter-on-quarter.
Medicalgorithmics, a Warsaw Stock Exchange-listed company, leader in cardiology diagnostic software, is dynamically scaling its operations while consistently executing its growth strategy, which includes the development and commercialization of cardiology diagnostic software based on proprietary AI algorithms. Since implementing the new strategy, the company has acquired 23 new clients, including 10 new contracts signed since the beginning of 2025. Preliminary data for Q1 2025 shows continued strong growth in the number of ECG tests: up 16% quarter-on-quarter and nearly 100% year-on-year, reaching approximately 92,000 ECG examinations.